Inhibitory effect of double transfection to xenoendothelial cells using both decay accelerating factor and homologous restriction factor 20 genes on complement dependent cytolysis

Journal of Surgical Research

Volumn 61, Issue 1, 1996, Pages 165-169

  Hayashi, Shuji ^a   Emi, Nobuhiko ^a   Isobe, Ken ichi ^a   Yokoyama, Itsuo ^a   Okada, Hidechika ^b   Takagi, Hiroshi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; LYMPHOCYTE ANTIGEN;

ANIMAL CELL; AORTA; ARTICLE; CATTLE; CELL PROTECTION; CELL VIABILITY; COMPLEMENT ACTIVATION; CYTOLYSIS; DNA TRANSFECTION; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SERUM; XENOGRAFT;

EID: 0030032635     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0099     Document Type: Article

References (30)

1. Bach, F. H. Revisiting a challenge in transplantation: Discordant xenografting. Hum. Immunol. 262: 30, 1991.
2. Platt, J. L., Vercellptti, G. M., Dalmasso, A. P., et al. Transplantation of discordant xenografts A review of progress. Immunol. Today 450: 11, 1990.
3. White, D. J. G., Oglesby, T., Liszewski, M. K., et al. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transplant. Proc. 474: 24, 1992.
4. Akami, T., Sawada, R., Minato, N., et al. Cytoprotective effect of CD59 antigen on xenotransplantation immunity. Transplant. Proc. 485: 24, 1992.
5. Takizawa, H., Takahashi, K., Murakami, T., Okada, N., and Okada, H. Species specific restriction of complement by HRF20 (CD59) generated by cDNA transfection. Eur. J. Immunol. 22: 1943, 1992.
6. Ratnoff, W. D., Fearon, D. T., and Austen, K. F. The role of antibody in the activation of the alternative complement pathway. Springer. Semin. Imunopathol. 6: 361, 1983.
7. Okada, N., Yasuda, T., and Okada, H. Antibody-mediated alternative complement pathway activation resists inhibition by sialoglycolipids. J. Immunol. 134: 3316, 1985.
8. Polhill, R. B., Newman, S. L., Pruitt, K M., and Johnston, R. B. Kinetic assessment of alternative complement pathway activity in a hemolytic system. J. Immunol. 121: 371, 1978.
9. Nelson, B., and Ruddy, S. Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. J. Immunol. 122: 1994, 1979.
10. Brooimans, R. A., Van Wieringen, P. A. M., Van Es, L. A., and Daha, M. R. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement mediated lysis. Eur. J. Immunol. 22: 3135, 1992.
11. Ryan, U. S. Isolation, culture, and subculture of bovine pulmonary artery endothelial cells: Mechanical methods. Tissue Cult. Methods 10: 3, 1986.
12. Medof, M. E., Kinoshita, T., and Nussenzweig, V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membrane. J. Exp. Med. 1558: 160, 1984.
13. Okada, H., Nagami, Y., Takahashi, K., et al. 20kDa homologous restriction factor of complement resembles T cell activating protein. Biochem. Biophys. Res. Commun. 162: 1553, 1989.
14. Li, X., Yee, J. K., Wolff, J. A., and Friedmann, T. Factors affecting long-term stability of Molony murine leukemia virus-based vectors. Virology 171: 331, 1989.
15. Yang, Z., Korman, A. J., Cooper, J., et al. Expression of HLA-DR antigen in human class II mutant B-cell lines by double infection with retrovirus vectors. Mol. Cell Biol. 7: 3923, 1987.
16. Shibuya, K., Abe, T., and Fujita, T. Decay-accelerating factor functions as a signal transducing molecule for human monocytes. J. Immunol. 149: 1758, 1992.
17. Harada, R., Okada, N., Fujita, T., and Okada, H. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. J. Immunol. 144: 1823, 1990.
18. Maniatis, T., Fritsch, F. F., and Sambrook, J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 9: 1982.
19. Abe, A., Takeo, T., Emi, N., et al. Transduction of a drug-sensitive toxic gene into human leukemia cell lines with a novel retroviral vector. P. S. E. B. M. 203: 354, 1993.
20. Hayashi, S., Ito, M., Yokoyama, I., and Takagi, H. Evidence that combination therapy using cobra venom factor, splenectomy and deoxyspergualin is effective in guinea pig to rat cardiac xenotransplantation. Transplantation 57: 777, 1994.
21. Pruitt, S. K., Baldwin III, W. M., Marsh, H. C., Lin, S. S., Yeh, C. G., and Bollinger, R. R. The effect of soluble complement receptor type I on hyperacute xenograft rejection. Transplantation 52: 868, 1991.
22. Miyagawa, S., Shirakura, R., Matsumiya, G., et al. Prolonging discordant xenograft survival with anti-complement reagents K76COOH and FUT175. Transplantation 55: 709, 1993.
23. Orr, F. W., and Warner, D. J. Effects of systemic complement activation and neutrophil-mediated pulmonary injury on the retention and metastasis of circulating cancer cells in mouse lungs. Lab. Invest. 62: 331, 1990.
24. Regal, J. F. Enhancement of antigen-induced bronchoconstriction in the guinea pig after intravascular complement activation with cobra venom factor. Int. Arch. Allergy Appl. Immunol. 91: 86, 1990.
25. White, D., and Wallwork, J. Xenografting: Probability, possibility, or pipe dream? Lancet 342: 879, 1993.
26. Dalmasso, A. P., Vercellotti, G. M., Fischel, R. J., Bolman, R. M., Bach, F. H., and Platt, J. L. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am. J. Pathol. 140: 1157, 1992.
27. Stefanova, I., and Horejsi, V. Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules. J. Immunol. 147: 1587, 1991.
28. Rooney, I. A., Liszewski, M. K., and Atkinson, J. P. Using membrane-bound complement regulatory proteins to inhibit rejection. Xeno 1: 29, 1993.
29. Nicholson-Weller, A., March, J. P., Rosenfeld, S. I., and Austen, K. F. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc. Natl. Acad. Sci. U.S.A. 80: 5066, 1983.
30. Yamashita, M., Ueda, E., Kinoshita, T., et al. Inherited complement deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. New Engl. J. Med. 323: 1184, 1990.